Hruby and Mac Hadley (University of Arizona, USA) in 19871989 Original development program Competitive Technologies Palatin Technologies , later spun off into PT-141 (bremelanotide) Target: non-selective agonist of MC1R, MC3R, MC4R, MC5R (more potent than -MSH, longer half-life) Standard experimental dose in human tanning studies: 0.025 mg/kg subcutaneously (Dorr 1996) In Dorr 1996 (n=10): increase in skin melanin density measured by colorimetry by ~25 % after a 10-day course Main adverse effects in the preclinical literature: nausea, flushing, hyperpigmentation (including atypical nevi), priapism Approximately 100+ publications in PubMed
Trends such as Semaglutide subscription plans are making it easier for individuals to commit to long-term weight management without the burden of frequent clinic visits
Ann.Indian Acad.Neurol
Miras AD, Prez-Pevida B, Aldhwayan M, Kamocka A, McGlone ER, Al-Najim W, et al
Q: What does GHK-CU stand for